Foghorn Therapeutics
Stock Forecast, Prediction & Price Target
Foghorn Therapeutics (FHTX) stock Price Target by analysts
$13
Potential upside: 176.00%
Foghorn Therapeutics price prediction
What is Foghorn Therapeutics stock analysts` prediction?
Foghorn Therapeutics stock forecast: Based on 1 Wall Street analysts` predicted price targets for Foghorn Therapeutics in the last 3 months, the avarage price target is $13, with a high forecast of $NaN. The average price target represents a 176.00% change from the last price of $4.71.
Disclaimer: This is not investment advice. Don't use price targets as the only investment indicator. Always remember to do your own thorough research and due diligence before making an investment decision.
Foghorn Therapeutics stock Price Target by analysts
Full breakdown of analysts given Foghorn Therapeutics price targets
| Analyst name & company | Analyst win rate | Publish date | Price target | Price when posted | Source | Historical targets |
|---|---|---|---|---|---|---|
Foghorn Therapeutics to $ H.C. Wainwright | 0% 0/1 | 9 months ago | $13 176.00% upside | $6.26 | TheFly | Previous targets (0) |
Vikram Purohit Morgan Stanley | 0% 0/2 | about 1 year ago | $9 91.08% upside | $9.32 | StreetInsider | Previous targets (1) |
Gavin Clark-Gartner Evercore ISI | 0% 0/1 | about 1 year ago | $20 324.62% upside | $6.26 | TheFly | Previous targets (0) |
Unknown BMO Capital | N/A | over 2 years ago | $20 324.62% upside | $6.53 | Benzinga | N/A |
Unknown Morgan Stanley | N/A | almost 3 years ago | $14 197.23% upside | $7.87 | Benzinga | N/A |
Vikram Purohit Morgan Stanley | 0% 0/2 | about 3 years ago | $15 218.47% upside | $10.89 | TheFly | Previous targets (1) |
Foghorn Therapeutics Financial Estimates
Foghorn Therapeutics Revenue Estimates
Foghorn Therapeutics EBITDA Estimates
Foghorn Therapeutics Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $1.31M N/A | $19.22M 1357.77% | $34.15M 77.63% | Avg: $34.03M Low: $19.83M High: $48.23M avg. -0.35% | Avg: $37.85M Low: $27.13M High: $48.61M avg. 11.23% | Avg: $95.15M Low: $68.19M High: $122.20M avg. 151.36% | Avg: $244.83M Low: $175.46M High: $314.41M avg. 157.28% |
Net Income
% change YoY
| $-103.22M N/A | $-108.87M -5.47% | $-98.42M 9.59% | Avg: $-110.00M Low: $-99.05M High: $-45.75M avg. -11.76% | Avg: $-115.64M Low: $-95.70M High: $-37.77M avg. -5.12% | Avg: $-40.71M Low: $-55.75M High: $-25.71M avg. 64.79% | Avg: $45.33M Low: $28.63M High: $62.08M avg. 211.34% |
EBITDA
% change YoY
| $-94.95M N/A | $-117.13M -23.36% | $-104.45M 10.82% | Avg: $-20.42M Low: $-28.94M High: $-11.89M avg. 80.45% | Avg: $-22.71M Low: $-29.16M High: $-16.27M avg. -11.23% | Avg: $-57.09M Low: $-73.32M High: $-40.91M avg. -151.36% | Avg: $-146.89M Low: $-188.64M High: $-105.27M avg. -157.28% |
EPS
% change YoY
| -$2.78 N/A | -$2.62 5.75% | -$2.34 10.68% | Avg: -$1.58 Low: -$2.36 High: -$1.09 avg. 32.58% | Avg: -$1.45 Low: -$2.28 High: -$0.9 avg. 8.08% | Avg: -$0.97 Low: -$1.33 High: -$0.61 avg. 33.10% | Avg: $1.08 Low: $0.68 High: $1.48 avg. 211.34% |
Operating Expenses
% change YoY
| $102.05M N/A | $136.36M 33.62% | $142.06M 4.17% | Avg: $313.25M Low: $182.52M High: $443.97M avg. 120.50% | Avg: $348.44M Low: $249.71M High: $447.47M avg. 11.23% | Avg: $875.86M Low: $627.70M High: $1.12B avg. 151.36% | Avg: $2.25B Low: $1.61B High: $2.89B avg. 157.28% |
FAQ
What is Foghorn Therapeutics stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 64.80% in 2025-2028.
We have gathered data from 4 analysts. Their low estimate is -99.05M, average is -110.00M and high is -45.75M.
What is Foghorn Therapeutics stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 79.88% in 2025-2028.
We have gathered data from 4 analysts. Their low revenue estimate is $19.83M, average is $34.03M and high is $48.23M.
What is Foghorn Therapeutics stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 71.27% in 2025-2028.
We have gathered data from 4 analysts. Their low earnings per share estimate is -$2.36, average is -$1.58 and high is $-1.09.
What is the best performing analyst?
In the last twelve months 1 analysts have been covering Foghorn Therapeutics stock. The most successful analyst is Foghorn Therapeutics to $.